More recently, GACAT3 was reported to be abnormally expressed in many malignant tumors, including gastric cancer, hepatocellular carcinoma, colorectal cancer, breast cancer, bladder cancer, glioma, ovarian cancer, and non-small cell lung cancer (Klymenko et al., 2017). Here, GACAT3 is linked to urinary bladder carcinoma.